Let's Talk
Let’s Talk

Author: gaurav

Untargeted Metabolomics Services for an Unprecedented Scale of Biomarker Discovery

Sapient leverages its next-generation mass spectrometry approaches to probe deeper into the human metabolome at a rate is unmatched for discovery, uncovering previously unknown biomarkers that associate with early disease, disease progression, and drug response. By enabling sponsors rapidly identify, validate, and translate these novel biomarkers, we help accelerate their drug development programs, enrich clinical… Continue reading Untargeted Metabolomics Services for an Unprecedented Scale of Biomarker Discovery

Sapient’s Diagnostic Collaboration with Bay Area Lyme Foundation Featured in the Foundation’s Annual Impact Update Report

San Diego, CA—Sapient, a full-service bioanalytical organization transforming drug development through biomarker discovery, has been featured in the Bay Area Lyme Foundation’s 2021 Impact Update report for its collaboration with the Foundation aimed at establishing new diagnostics for persistent Lyme disease (PLD). The report shares insight into the research being conducted by Sapient in leveraging Bay Area… Continue reading Sapient’s Diagnostic Collaboration with Bay Area Lyme Foundation Featured in the Foundation’s Annual Impact Update Report

Platform Explainer: How Sapient Accelerates Biomarker Discovery

At Sapient, we believe biomarker-driven drug development can transform lives – and accelerate the process at a fraction of the time and cost. That’s why we’ve built a Discovery Engine to enable circulating biomarker discovery at unprecedented speed and scale.  Watch to learn why we focus on small molecule biomarkers, how our biomarker discovery platform works, and… Continue reading Platform Explainer: How Sapient Accelerates Biomarker Discovery

Biomarker-Driven Clinical Trials: Enriched with Biology, Evolved for a New Era

Why are large, expensive clinical trials so common? It stems from the challenge of needing to demonstrate treatment efficacy in enough of the patient population despite the fact that a majority of patients are likely to be non-responders. The FDA generally expects at least 35% of patients in a trial to be “responders” in order to… Continue reading Biomarker-Driven Clinical Trials: Enriched with Biology, Evolved for a New Era

Large Scale Biomarker Discovery: Next-Gen Mass Spectrometry Profiling to Accelerate Drug Development

Now On Demand | Hosted by AAPS Circulating biomarker discovery is a critical component of the drug discovery process, identifying markers that improve our understanding of complex disease processes and enable personalization of therapy, evaluation of target engagement, clinical trial enrichment, and more. To date, however, large scale discovery of circulating biomarkers has been limited by bioanalytical constraints… Continue reading Large Scale Biomarker Discovery: Next-Gen Mass Spectrometry Profiling to Accelerate Drug Development

Getting Drug Development Right

The omics revolution has enabled many breakthroughs in our understanding of disease biology, but the productivity of clinical drug development remains historically low. In 2020, the composite success rate of drugs across all therapy areas was only 9.8% – even lower than the 10-year average of 12.9%. Figure 1. Clinical Development Productivity Index by phase and overall.… Continue reading Getting Drug Development Right

Deep Neural Networks for Classification of LC-MS Spectral Peaks

Nontargeted LC-MS can assay thousands of chemical entities in a single biospecimen, but in that crush of data, how do you isolate true spectral features from the noise? This paper, contributed to by Sapient’s scientists, describes machine learning-based approaches found to remove up to 90% of false peaks without reducing true positive signals, with excellent… Continue reading Deep Neural Networks for Classification of LC-MS Spectral Peaks

Let's Talk